+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Anti-Hypertensive Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

  • PDF Icon

    Report

  • 117 Pages
  • August 2022
  • Region: Global
  • Acute Market Reports
  • ID: 5707258
Hypertension is most commonly observed chronic disease, which causes elevation in systolic and diastolic blood pressure, which in long term is high risk factor for coronary artery disease, heart failure, stroke etc.. The anti-hypertensive drugs are used to control the blood pressure. The antihypertensive drugs market major drivers is the prevalence of the chronic disease along with growing population and altering lifestyle, with increase in awareness of treatment, new drug approval and healthcare expenditure.

The report titled Global Anti-Hypertensive Drugs Market - Growth, Share, Opportunities and Competitive Analysis, 2022 - 2030 offers strategic insights into the overall anti-hypertensive drugs market along with the market size and estimates for the duration 2022 to 2030. The said research study covers in-depth analysis of multiple market segments based on type of drug class and different geographical region. The Drug class type segment studied for analyzing the overall anti-hypertensive drugs market is majorly segmented into Diuretics, Angiotensin receptor blockers (ARBs), Angiotensin converting enzyme (ACE) inhibitors, Beta blockers, Alpha blockers, Calcium channel blockers, Renin inhibitors and Vasodilators.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global anti-hypertensive drugs market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global anti-hypertensive drugs market. This report concludes with company profiles section that highlights major information about the key players engaged in global anti-hypertensive drugs market. In-depth competitive environment analysis and historical years (2020 & 2021) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global anti-hypertensive drug market, offering market size and estimates for the period from 2022 to 2030, keeping in mind the above-mentioned factors.

The global Anti-Hypertensive Drugs market is segmented by drug class into different categories such as Diuretics, Angiotensin receptor blockers (ARBs), Angiotensin converting enzyme (ACE) inhibitors, Beta blockers, Alpha blockers, Calcium channel blockers, Renin inhibitors and Vasodilators. The ACE inhibitors controls the blood pressure by the by widening the blood vessel, which improve the blood flood of the heart. ACE inhibitor dominates the market share of the antihypertensive drugs market in value due to its mechanism of action, preference in geriatric population and cost. The next followed is beta blockers in antihypertensive drugs market which preferred by physician to reduce the blood pressure and risk of complication which is generally associated with chronic hypertension is less, plus with minimal side effects. Diuretic is next most commonly used anti-hypertensive drug in the market, as they are widely available and less expensive compared to others. The diuretics help in maintain the blood pressure by getting rid of the sodium and water. Diuretic is conventionally used first line of treatment, though the trend is changing with new drug entrants approval and different mechanism of action which is further preferred by physician depending upon the suitability of the patient medical history; due to which ACE, Beta blocker, CCB, ARB etc. are used now-days and exist in market according to patient needs.

The global anti-hypertensive drugs market is bifurcated into four regions: North America, Europe, Asia-Pacific, Latin America and Middle East. The global Anti-Hypertensive Drug market is dominated by the North America region occupying the major market. The major contributor in this region is US due to factors such as the prevalence of hypertension, rise in geriatric population, upcoming new drug in pipeline and use of combination therapy. Europe is next followed up market with major contributor being UK, Germany, France, Italy and Spain. According to research studies, with rise in population of Europe, there is considerable increase in number of people suffering from hypertension, therefore to address the unmet need for appropriate health care planning and expenditure are the major driving factors for the European market. The Asia-pacific is the lucrative market, with major contributors being Japan, India and China. Asia-Pacific carries almost half of the world cardiovascular burden, in which upto 66% of subtype of CVD contribute to hypertension due to increase in urbanization and adoption of unhealthy lifestyle and food. Thus developed countries dominates the market of hypertensive, emerging economies with growing population and increasing government spending on health care is lucrative market.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Anti-Hypertensive Drugs market are as follows:
  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Anti-Hypertensive Drugs market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug

  • Diuretics
  • ACE inhibitors
  • ARBs
  • Calcium Channel Blockers
  • Beta - Adrenergic blocker
  • Alpha - Adrenergic blocker
  • Central Sympatholyics
  • Renin inhibitors
  • Vasodilators

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Anti-Hypertensive Drugs market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Anti-Hypertensive Drugs market?
  • Which is the largest regional market for Anti-Hypertensive Drugs market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Anti-Hypertensive Drugs market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Anti-Hypertensive Drugs market worldwide?


This product will be delivered within 2 business days.

Table of Contents

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Anti-Hypertensive Drugs Market
2.2. Global Anti-Hypertensive Drugs Market, By Drug, 2021 (US$ Million)
2.3. Global Anti-Hypertensive Drugs Market, By Geography, 2021 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2021
3. Anti-Hypertensive Drugs Market: Competitive Analysis
3.1. Market Positioning of Key Anti-Hypertensive Drugs Market Vendors
3.2. Strategies Adopted by Anti-Hypertensive Drugs Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. Anti-Hypertensive Drugs Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Anti-Hypertensive Drugs Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Diuretics
5.3.2. ACE inhibitors
5.3.3. ARBs
5.3.4. Calcium Channel Blockers
5.3.5. Beta - Adrenergic blocker
5.3.6. Alpha - Adrenergic blocker
5.3.7. Central Sympatholyics
5.3.8. Renin inhibitors
5.3.9. Vasodilators
6. North America Anti-Hypertensive Drugs Market, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
6.3.Anti-Hypertensive Drugs Market: By Region, 2020-2030, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
7. UK and European Union Anti-Hypertensive Drugs Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
7.3.Anti-Hypertensive Drugs Market: By Region, 2020-2030, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
7.3.1.5. France
7.3.1.5.1. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
8. Asia Pacific Anti-Hypertensive Drugs Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
8.3.Anti-Hypertensive Drugs Market: By Region, 2020-2030, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
8.3.1.3. India
8.3.1.3.1. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
9. Latin America Anti-Hypertensive Drugs Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
9.3.Anti-Hypertensive Drugs Market: By Region, 2020-2030, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
10. Middle East and Africa Anti-Hypertensive Drugs Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
10.3.Anti-Hypertensive Drugs Market: By Region, 2020-2030, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
11. Company Profile
11.1. Novartis AG
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Astra zeneca
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Daiichyi Sankyo Co. Ltd
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Takeda Pharmaceutical
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Sanofi
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Merck & Co
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Boehinger Ingelheim
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Pfizer
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Bayer AG
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Lupin Limited
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Johnson & Johnson
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
11.12. Actelion Ltd
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Portfolio
11.12.4. Strategic Initiatives
11.13. Ranbaxy Laboratories Limited
11.13.1. Company Overview
11.13.2. Financial Performance
11.13.3. Product Portfolio
11.13.4. Strategic Initiatives
11.14. Other Notable Players
11.14.1. Company Overview
11.14.2. Financial Performance
11.14.3. Product Portfolio
11.14.4. Strategic Initiatives
List of Figures
Figure 1 Global Anti-Hypertensive Drugs Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Anti-Hypertensive Drugs Market: Quality Assurance
Figure 5 Global Anti-Hypertensive Drugs Market, By Drug, 2021
Figure 6 Global Anti-Hypertensive Drugs Market, By Geography, 2021
Figure 7 Market Geographical Opportunity Matrix - Global Anti-Hypertensive Drugs Market, 2021
Figure 8 Market Positioning of Key Anti-Hypertensive Drugs Market Players, 2021
Figure 9 Global Anti-Hypertensive Drugs Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 10 Global Anti-Hypertensive Drugs Market, By Drug, 2021 Vs 2030, %
Figure 11 U.S. Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
Figure 12 Canada Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
Figure 13 Rest of North America Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
Figure 14 UK Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
Figure 15 Germany Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
Figure 16 Spain Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
Figure 17 Italy Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
Figure 18 France Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
Figure 19 Rest of Europe Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
Figure 20 China Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
Figure 21 Japan Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
Figure 22 India Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
Figure 23 Australia Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
Figure 24 South Korea Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
Figure 25 Rest of Asia Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
Figure 26 Brazil Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
Figure 27 Mexico Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
Figure 28 Rest of Latin America Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
Figure 29 GCC Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
Figure 30 Africa Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
Figure 31 Rest of Middle East and Africa Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
List of Tables
Table 1 Global Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 2 North America Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 3 U.S. Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 4 Canada Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 5 Rest of North America Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 6 UK and European Union Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 7 UK Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 8 Germany Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 9 Spain Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 10 Italy Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 11 France Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 12 Rest of Europe Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 13 Asia Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 14 China Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 15 Japan Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 16 India Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 17 Australia Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 18 South Korea Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 19 Latin America Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 20 Brazil Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 21 Mexico Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 22 Rest of Latin America Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 23 Middle East and Africa Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 24 GCC Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 25 Africa Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
Table 26 Rest of Middle East and Africa Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)

Companies Mentioned

  • Novartis AG
  • Astra zeneca
  • Daiichyi Sankyo Co. Ltd
  • Takeda Pharmaceutical
  • Sanofi
  • Merck & Co
  • Boehinger Ingelheim
  • Pfizer
  • Bayer AG
  • Lupin Limited
  • Johnson & Johnson
  • Actelion Ltd
  • Ranbaxy Laboratories Limited